Dr Nick Wickham

Clinical Haematologist
Become a Patient

Dr Nick Wickham is dedicated to providing his patients with timely access to best practice haematological care.


Dr Nick Wickham is an experienced clinical haematologist at Icon Cancer Centre Windsor Gardens. Nick trained in medicine at Cambridge where he worked as a research assistant at the Physiological Laboratory, investigating the properties of artificial fluorocarbon blood substitutes. He undertook advanced clinical and laboratory haematology training at London’s Royal Postgraduate Medical School, Hammersmith Hospital, St George’s Hospital Medical School and Royal Marsden Hospital. He subsequently completed a two-year research fellowship at the University of Minnesota Hospital where he investigated endothelial cell signal transduction in response to inflammatory and thrombotic mediators.

During Nick’s appointment as senior lecturer at the Chinese University of Hong Kong’s Department of Oncology, he established the adult leukaemia service and high dose therapy with stem cell transplantation at the Prince of Wales Hospital from 1993 to 1997. In 1998 he relocated to Australia to commence as a senior consultant haematologist at The Queen Elizabeth Hospital. In 2000 Nick moved to Townsville to become Director of Haematology-Oncology and Chairman of the North Queensland Oncology Service until he returned to Adelaide in July 2003. He then joined Icon Cancer Centre (formerly Adelaide Cancer Centre) and subsequently held the title of Clinical Associate Professor with the University of Adelaide Medical School between 2008 and 2018.

Nick maintains a strong interest in medical education and research, publishing over 80 articles and several book chapters. He was CEO of Clinpath Laboratories from 2010 until 2015 while continuing to consult at Icon Cancer Centre on a part-time basis. Following a nine-month sabbatical from September 2020, Nick joined SA Health as a Medical Consultant with the Covid Operations Unit within the Communicable Disease Control Branch. Nick is also a member of the Doctors for Environment Australia (DEA) and is on the committee for Medical Association for Prevention of War (MAPA) and is a Fellow of the Royal Society of Arts, Manufactures and Commerce (FRSA) which is committed to finding practical solution to social challenges.

He is experienced in caring for a wide range of malignant and non-malignant blood disorders with a special interest in myelodysplasia, chronic leukaemias, lymphoma, multiple myeloma, thrombosis and haemostasis, and autoimmune disorders.

Affiliations & Memberships

  • American Society of Hematology (ASH)
  • Doctors for Environment Australia (DEA)
  • European Hematology Association (EHA)
  • Haematology Society of Australia and New Zealand (HSANZ)
  • Medical Association for Prevention of War (MAPA)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologists of Australasia (RCPA)
  • Royal Society of Arts, Manufactures and Commerce (FRSA)

Special Interests

Dr Nick Wickham accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Leukaemia
  • Lymphoma
  • Multiple myeloma
  • Myelodysplasia
  • Thrombosis and haemostasis

Icon Locations

Adelaide (Windsor Gardens) View centre


  • Artificial blood from fluorocarbons. N.W.R. Wickham & R.N Hardy. Hospital Update, 1982:1433-1444.

  • Measurement of intracellular calcium concentration in intact monolayers of human endothelial cells. N.W.R. Wickham, G.M. Vercellotti, C.F. Moldow, M.R. Visser & H.S. Jacob. Journal of Laboratory and Clinical Medicine, 1988; 112: 157-167.

  • Monoclonal gammopathy of unknown significance and malignant paraproteinaemia in Hong Kong. Y.I. Loin, J. Chow & N.W.R Wickham. American Journal of Clinical Pathology, 1996; 106 (4): 449-456.

  • Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. N.W.R Wickham, A.S. Gallus, B.N.J Walters, A. Wilson & NHMRC VTE Prevention Guideline Adaptation Committee. Journal of Internal Medicine, 2012; 42(6): 698-708.

  • Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies. C.Y. Cheah, N.W.R. Wickham, C.K. Yannakou, K.L. Lewis, C-H. Hui, P.S. Tang, T. Turpuseema, H.P. Miskin, J-P. Tang, E. Norman, A.D. Ricart & C. Tam. Blood, 2019; 134 Supplement: 4001.